breast-cancer-2018-scientifictracks-abstracts

19 / 19

Page 62
Notes:
conferenceseries.com
Volume 10 Journal of Cancer Science & Therapy
ISSN: 1948-5956 Breast Cancer 2018
May 10-11, 2018
May 10-11, 2018 | Frankfurt, Germany
7th World Congress on Breast Cancer
Expression of ganglioside GD2, as a novel cancer stem cell marker in breast carcinomas
Mansoori M
Iran University of Medical Sciences, Iran
Introduction: Cancer stem cells (CSCs) are attractive for many researchers because of their diagnostic, prognostic and
therapeutic implications. Here, we aim to investigate the local expression of ganglioside GD2, as the recently proposed breast
CSC (BCSC) marker, through the assessment of GD2 synthase mRNA, the key enzyme involved in GD2 synthesis.
Material & Methods: Fresh tumor tissues along with normal adjacent tissues from 65 patients who underwent surgery for
breast cancer were collected. Total RNAs of tumoral and normal tissue samples were extracted and analyzed using real-time
PCR. The mRNA expression pattern of GD2 was compared in tumoral and control tissue samples using ΔΔCT method. The
relevance of GD2 synthase level with clinical characteristics of the patients was also evaluated.
Results: The expression level of GD2 synthase was significantly higher in breast cancer tissue samples compared to normal
adjacent tissues (4.92-fold change, p<0.001). GD2 synthase expression was also significantly higher in advanced grades tumor
(2 and 3) (p=0.001) and in patients at stages III and IV compared to stages I and II (p=0.001). Whereas, the correlation between
GD2 synthase and other clinicopathologic data was not statistically significant, such as for age (p=1.000), type of carcinoma
(p=0.934), lymphatic invasion (p=0.139) and tumor size (p=0.066).
Conclusion: The higher expression of GD2 synthase in tumoral tissue samples of breast cancer patients further potentiates it
as a BCSC marker which could be used for clinical implications such as diagnosis, monitoring and prognosis of breast cancer.
Biography
Mansoori M is pursuing her last semester of PhD in Iran University of Medical Sciences, Tehran Iran. She has ranked 5th in PhD entrance exam among 500
candidates. She has published four papers in reputed journals.
Mansoori M, J Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C2-126